Previous 10 | Next 10 |
2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
2023-09-28 17:02:15 ET Summary Morphic Holding, Inc.'s stock has dropped 61% in just 2 months, calling into question its $3bn valuation. The company's lead asset, MORF-057, targets the integrin α4β7, but faces tough competition from the biologic drug Vedolizumab. ...
2023-09-27 05:47:01 ET Related stories MillerKnoll, Inc. (MLKN) Q1 2024 Earnings Call Transcript MillerKnoll Stock: On A Roll Cardiff Oncology (CRDF) Investor Presentation - Slideshow Connecting The Dots: Markets React To Hawkish Revisions In The Fed's Intere...
2023-09-26 16:44:17 ET More on Morphic Seeking Alpha’s Quant Rating on Morphic Historical earnings data for Morphic Financial information for Morphic Morphic: High Valuation Not Justified By Data, Development Status, Or Cash Morphic cut to Neut...
WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is expected to return to his role as Chief Exec...
2023-09-25 14:56:13 ET Extending a sharp decline from last week, Morphic Holding ( NASDAQ: MORF ) continued to trade lower Monday as BTIG downgraded the biotech, citing questions on the potential of its lead asset, MORF-057, targeted at ulcerative colitis (UC). The analyst Jul...
2023-09-25 13:00:22 ET Gainers: Vaccitech plc ADR ( VACC ) +93% . ESS Tech ( GWH ) +23% . Flora Growth Corp ( FLGC ) +22% . Avalo Therapeutics ( AVTX ) +22% . Neuraxis ( NRXS ) +19% . American Coastal Insurance Corp ( ACIC ...
2023-09-25 09:59:16 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecuti...
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen across key measures at week 12, mMCS response of 45.7% and endoscopic improvement of 25.7%- ...
2023-09-22 15:27:43 ET More on Morphic Seeking Alpha’s Quant Rating on Morphic Historical earnings data for Morphic Financial information for Morphic Morphic: High Valuation Not Justified By Data, Development Status, Or Cash Stifel cuts Morphic...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:15:05 ET RBC Capital analyst issues SECTOR PERFORM recommendation for MORF on July 9, 2024 06:29AM ET. The previous analyst recommendation was Outperform. MORF was trading at $55.74 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-07-08 20:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $57.00 for MORF on 2024-07-08 18:49:00. The adjusted price target was set to $57.00. At the time of the announcement, MORF was trading at $55.74. The overall price target consensus is at $...